Abstract
<h3>Objective:</h3> To evaluate patients’ perceptions and knowledge regarding palliative and end-of-life care in Parkinson’s disease <h3>Background:</h3> Palliative care is receiving a growing interest in PD. Little is known, however, about PD patients’ perceptions, knowledge or experience. Until now, no study has been carried out in France to assess (i) if PD patients talk about these topics with healthcare professionals or their families, (ii) or if they use the available legal documents (advance directives and trusted person). Understanding the current situation is critical to identify levers for action and improve patients’ access to palliative care resources. <h3>Design/Methods:</h3> Anonymous online questionnaire (available for 10 days), with the survey link sent by email to participants through various PD patients’ associations (France Parkinson, APIV) and home healthcare provider nurses <h3>Results:</h3> 60 patients (51.7% women, 56.7% over 70 years old) voluntarily completed the survey. The majority of patients do not consider themselves well informed about palliative care (68.3%). They never discuss palliative care with their medical team (86.7%) nor their family (68.3%). However, they think they can benefit from palliative care because of their illness (65%) and want more information on this subject (58.3%). Most patients have already thought about the end of life (71.%) and find it scary (68.3%). They never have end-of-life discussions with their medical team (80%) or their family (51.7%). They have never received any documentation from professionals (58.3%). Only 51.7% are aware of the existence of an end-of-life law. Although they consider it important, few patients have already designated their trusted person (38.3%) or written their advance directives (15%). <h3>Conclusions:</h3> This small survey highlights a practice gap. PD patients are not well informed about palliative care services. Medical teams (including neurology) need to take ownership of the subject and help patients and their families talk about these issues, even if they seem frightening. <b>Disclosure:</b> Dr. Auffret has received personal compensation for serving as an employee of France Développement Electronique. The institution of Dr. Auffret has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Britannia. Dr. Auffret has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Britannia. Dr. Auffret has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Britannia. Dr. Auffret has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Aguettant. The institution of Dr. Auffret has received research support from Association France Parkinson. The institution of Dr. Auffret has received research support from Homeperf. The institution of Dr. Auffret has received research support from LVL. The institution of Dr. Auffret has received research support from University of Rennes 1. The institution of Dr. Auffret has received research support from Aguettant. The institution of Dr. Auffret has received research support from Linde. The institution of Dr. Auffret has received research support from Plateforme Nationale pour la recherche sur la fin de vie. Dr. Auffret has received publishing royalties from a publication relating to health care. Guillaume Robert has nothing to disclose. Matthieu Bereau has nothing to disclose. Mr. Verin has nothing to disclose.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.